2 Stocks That Could Soar This Year
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen to (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers' shares even beyond the next 12 months. Let's find out more.
Image source: Getty Images.
Source Fool.com
Exelixis Inc. Stock
€37.03
-1.650%
The stock is one of the favorites of our community with 31 Buy predictions and 1 Sell predictions.
As a result the target price of 41 € shows a slightly positive potential of 10.72% compared to the current price of 37.03 € for Exelixis Inc..
